Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer

Journal of Thoracic Oncology

Volumn 12, Issue 8, 2017, Pages 1223-1232

  Feller Kopman, David ^a   Liu, Shan ^b,c   Geisler, Benjamin P ^b,d   DeCamp, Malcolm M ^e   Pietzsch, Jan B ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Wing Tech Inc   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bronchoscopy; Cost effectiveness; Diagnostic techniques; Genetic marker; Lung cancer

Indexed keywords

ADULT; ARTICLE; BRONCHOSCOPY; CANCER CLASSIFICATION; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; GENOMICS; HUMAN; INTERMEDIATE RISK PATIENT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; THORACOSCOPY; COST BENEFIT ANALYSIS; ECONOMICS; GENETIC MARKER; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROCEDURES;

BRONCHOSCOPY; COST-BENEFIT ANALYSIS; FEMALE; GENETIC MARKERS; GENOMICS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 85020071073     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2017.04.030     Document Type: Article

References (32)

1. Rivera, M.P., Mehta, A.C., Wahidi, M.M., Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143 (2013), e142S–e165S.
2. Tukey, M.H., Wiener, R.S., Population-based estimates of transbronchial lung biopsy utilization and complications. Respir Med 106 (2012), 1559–1565.
3. Grogan, E.L., Weinstein, J.J., Deppen, S.A., et al. Thoracic operations for pulmonary nodules are frequently not futile in patients with benign disease. J Thorac Oncol 6 (2011), 1720–1725.
4. Silvestri, G.A., Vachani, A., Whitney, D., et al. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med 373 (2015), 243–251.
5. Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C., (eds.) Cost-effectiveness in Health and Medicine, 1996, Oxford University Press, New York, NY.
6. Cohen, D.J., Reynolds, M.R., Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol 52 (2008), 2119–2126.
7. Neumann, P.J., Cohen, J.T., Weinstein, M.C., Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 371 (2014), 796–797.
8. Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2304–2322.
9. Hill, S.R., Olson, L.G., Falck-Ytter, Y., et al. Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc 9 (2012), 251–255.
10. Weinstein, M.C., O'Brien, B., Hornberger, J., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health 6 (2003), 9–17.
11. Gould, M.K., Sanders, G.D., Barnett, P.G., et al. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med 138 (2003), 724–735.
12. Mahadevia, P.J., Fleisher, L.A., Frick, K.D., Eng, J., Goodman, S.N., Powe, N.R., Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 289 (2003), 313–322.
13. Menezes, R.J., Roberts, H.C., Paul, N.S., et al. Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience. Lung Cancer 67 (2010), 177–183.
14. Facey, K., Bradbury, I., Laking, G., Payne, E., Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess, 11, 2007 iii–iv, xi–267.
15. Bastarrika, G., Garcia-Velloso, M.J., Lozano, M.D., et al. Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med 171 (2005), 1378–1383.
16. Bugalho, A., Ferreira, D., Eberhardt, R., et al. Diagnostic value of endobronchial and endoscopic ultrasound-guided fine needle aspiration for accessible lung cancer lesions after non-diagnostic conventional techniques: a prospective study. BMC Cancer, 13, 2013, 130.
17. Ferguson, J.S., Van Wert, R., Choi, Y., et al. Impact of a bronchial genomic classifier on clinical decision making in patients undergoing diagnostic evaluation for lung cancer. BMC Pulm Med, 16, 2016, 66.
18. Phillips, J.D., Merkow, R.P., Sherman, K.L., DeCamp, M.M., Bentrem, D.J., Bilimoria, K.Y., Factors affecting selection of operative approach and subsequent short-term outcomes after anatomic resection for lung cancer. J Am Coll Surg 215 (2012), 206–215.
19. Fernandez, F.G., Kosinski, A.S., Burfeind, W., et al. The Society of Thoracic Surgeons lung cancer resection risk model: higher quality data and superior outcomes. Ann Thorac Surg 102 (2016), 370–377.
20. Goldstraw, P., Crowley, J., Chansky, K., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2 (2007), 706–714.
21. Deppen, S.A., Davis, W.T., Green, E.A., et al. Cost-effectiveness of initial diagnostic strategies for pulmonary nodules presenting to thoracic surgeons. Ann Thorac Surg 98 (2014), 1214–1222.
22. Yang, C.F., Sun, Z., Speicher, P.J., et al. Use and outcomes of minimally invasive lobectomy for stage I non-small cell lung cancer in the National Cancer Data Base. Ann Thorac Surg 101 (2016), 1037–1042.
23. Lee, P., Mehta, A.C., Mathur, P.N., Management of complications from diagnostic and interventional bronchoscopy. Respirology 14 (2009), 940–953.
24. Sullivan, P.W., Ghushchyan, V., Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 26 (2006), 410–420.
25. Mazzone, P.J., Obuchowski, N., Fu, A.Z., Phillips, M., Meziane, M., Quality of life and healthcare use in a randomized controlled lung cancer screening study. Ann Am Thorac Soc 10 (2013), 324–329.
26. Bendixen, M., Jorgensen, O.D., Kronborg, C., Andersen, C., Licht, P.B., Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol 17 (2016), 836–844.
27. Wiener, R.S., Schwartz, L.M., Woloshin, S., Welch, H.G., Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med 155 (2011), 137–144.
28. Ost, D.E., Ernst, A., Lei, X., et al. Diagnostic yield and complications of bronchoscopy for peripheral lung lesions. Results of the AQuIRE Registry. Am J Respir Crit Care Med 193 (2016), 68–77.
29. Wang Memoli, J.S., Nietert, P.J., Silvestri, G.A., Meta-analysis of guided bronchoscopy for the evaluation of the pulmonary nodule. Chest 142 (2012), 385–393.
30. Yip, L., Farris, C., Kabaker, A.S., et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab 97 (2012), 1905–1912.
31. Li, H., Robinson, K.A., Anton, B., Saldanha, I.J., Ladenson, P.W., Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 96 (2011), E1719–E1726.
32. Labourier, E., Utility and cost-effectiveness of molecular testing in thyroid nodules with indeterminate cytology. Clin Endocrinol (Oxf) 85 (2016), 624–631.